INVO Fertility, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 22, 2026, regarding INVO Fertility, Inc. (Nasdaq: IVF). The filing details the results of a Special Meeting of Stockholders held on that date and the subsequent amendment to the Company's Articles of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes and Corporate Actions
Shareholders approved five key proposals at the Special Meeting, resulting in the following material changes:
- Authorized Share Increase: The number of authorized common shares was increased from 6,250,000 to 250,000,000 shares via a Certificate of Amendment filed on January 22, 2026.
- Warrant Issuance Approval: Shareholders approved the issuance of up to 4,733,728 shares of common stock upon exercise of a warrant issued to investors in a private placement closed on December 4, 2025.
- Stock Incentive Plan Expansion: The 2019 Stock Incentive Plan was amended to increase the total shares available for issuance to 1,000,000 (approximately 10% of fully-diluted outstanding stock).
- Accountant Ratification: WithumSmith+Brown, PC was ratified as the independent public accountant for the fiscal year ending December 31, 2025.
Voting Results Summary
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| 1. Ratify Accountant | 865,418 | 39,637 | 38,999 | N/A |
| 2. Warrant Issuance | 118,385 | 75,191 | 1,343 | 514,135 |
| 3. Increase Authorized Shares | 663,861 | 279,474 | 719 | N/A |
| 4. Stock Plan Amendment | 349,649 | 79,894 | 376 | 514,135 |
| 5. Adjournment Proposal | 732,663 | 187,102 | 24,289 | N/A |
Note: A quorum of 944,054 shares was established. The Adjournment Proposal was not required as all substantive proposals passed.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future financial outlook, specific risks, or contingencies beyond the standard incorporation of the Amendment text by reference. The approval of the warrant issuance suggests the Company is proceeding with capital raising activities initiated in December 2025.
Key Facts for Investor Verification
- Verify the impact of the 39x increase in authorized shares (from 6.25M to 250M) on potential future dilution.
- Review the terms of the private placement warrant approved in Proposal 2, specifically the exercise price and expiration date, to assess potential dilution from the 4.7M shares.
- Confirm the current outstanding share count to understand the 10% fully-diluted basis calculation for the new Stock Incentive Plan.
- Check subsequent filings for the actual issuance of shares related to the warrant exercise.